How do I respond in Spanish when a heart failure patient says he could not afford to fill his Entresto or sacubitril/valsartan?

Receive the disclosure without shame and move immediately to options: “Entiendo — y tiene razón en decirme eso; hay varias maneras de resolver esto y yo quiero que lo intentemos juntos. La primera cosa que quiero hacer es ver si usted califica para el programa del fabricante — se llama Entresto Together, y para muchos pacientes baja el costo a cero o a muy poco. ¿Me permite que lo revisemos hoy mismo?” The three pathways worth knowing: (1) manufacturer patient-assistance programs (Novartis Entresto Together and others) can reduce or eliminate cost for eligible patients; (2) 340B pharmacies serve qualifying patients at significantly reduced prices; (3) if the ARNI is truly inaccessible, an ACE inhibitor or ARB is a guideline-supported alternative that keeps the patient on a RAAS-blocking agent while the cost barrier is resolved. The goal of the visit is that the patient leaves with a medication he will actually take.

What do I say in Spanish when a heart failure patient tells me he only takes his furosemide on days he is not working?

Acknowledge the constraint before the mechanism: “Tiene sentido — si maneja un bus, no puede parar cada hora. Eso no es excusa, es la realidad. Lo que me preocupa es lo que pasó con el líquido mientras el furosemide no estaba trabajando, y quiero que hablemos de cómo resolver eso de verdad — no de una manera que le haga imposible trabajar.” The approach that works: separating dose from timing. A patient who takes furosemide only on his days off is not non-compliant by personality — he is solving a real problem with an incomplete tool. Evening dosing after the shift ends, dose-timing adjustment through the physician, and explicit permission to call the clinic when a work constraint creates a clinical tension are all options. Document the constraint exactly as the patient described it so the prescriber can modify the regimen with accurate information.

How do I explain in Spanish why a patient with heart failure is being prescribed a beta-blocker that the pharmacy printout says can cause heart failure?

The mechanism explanation that resolves the paradox: “La lista de efectos secundarios la escribieron para todas las personas que toman este medicamento — incluyendo personas sin insuficiencia cardíaca que lo toman para la presión. En esas personas, si la dosis es muy alta, el corazón puede verse afectado. Por eso aparece en la lista. Para usted — que ya tiene insuficiencia cardíaca — la dosis es diferente, el por qué es diferente, y el resultado es diferente.” Then the mechanism itself: a heart with reduced function beats too fast and too hard trying to compensate; beta-blockers slow it, which counterintuitively reduces the demand on it and allows it to fill better and eventually recover some function; the side-effect list was written for a different patient, at a different dose, for a different reason. “Lo que le doy a usted no es lo mismo que lo que describía esa lista — es el mismo nombre pero una indicación completamente diferente.”

What question should I ask at every heart failure follow-up to surface medication barriers a Spanish-speaking patient has not raised?

Three questions worth adding to any heart failure follow-up in Spanish: (1) “¿Pudo tomar todos sus medicamentos como le indicaron esta semana — o hubo alguno que fue difícil de conseguir, de pagar, o de tomar por alguna razón?” (2) “¿Hay alguna situación en que sea difícil tomar un medicamento — horario, trabajo, transporte, costo, algo que leyó?” (3) “¿Hubo alguno que no quiso tomar después de leer la lista de efectos secundarios?” The third question is the one most nurses do not ask, and it is the one that catches the patient who stopped a guideline-directed medication based on a pharmacy printout written for a different population.

How do I document a heart failure medication barrier in Spanish-speaking patients for the prescribing team?

Chart language that gives the prescriber what she needs: “Patient disclosed [medication name] not filled / not taken since [date] due to [cost / work-schedule constraint / side-effect concern after reading pharmacy printout]. Patient described [specific barrier in patient’s own words: e.g., ‘la farmacia cobró $450 y no lo piqué’ / ‘solo lo tomo los días que no trabajo porque no puedo ir al baño en el bus’ / ‘dice que causa falla cardíaca y yo ya la tengo’]. [Action taken: PAP enrollment initiated / dose-timing adjustment request flagged for cardiologist / mechanism explanation given, patient agreed to restart, follow-up call in 48 hours].” Documenting in the patient’s own words — even if you translate to English for the chart — preserves the specificity the prescriber needs to modify the regimen appropriately.

Blog — Clinical Spanish

Spanish for heart failure clinic nurses (the patient who is scared of his medications): the patient who did not fill the ARNI because of the cost, the patient who is rationing his diuretic to avoid the bathroom at work, and the patient who stopped his beta-blocker after reading the side-effect list

Tomás Guerrero was 62 years old, a retired construction laborer from Los Angeles who had worked concrete and framing for thirty-three years. He had been discharged from the hospital two weeks earlier with a diagnosis of heart failure with reduced ejection fraction, an EF of 32%, a new prescription for sacubitril/valsartan, and instructions to take his carvedilol, his furosemide, and the new medication every morning.

He had taken the carvedilol. He had taken the furosemide. He had not filled the sacubitril/valsartan.

He arrived at his two-week follow-up appointment having done almost everything right. When the nurse asked about his medications, he said: “El carvedilol sí, el diurético sí, el otro… fui a la farmacia y me dijeron cuatrocientos cincuenta dólares. Pensé que se habían equivocado. Pero cuando vi que no, lo dejé ahí.”

(The carvedilol yes, the diuretic yes, the other one… I went to the pharmacy and they told me four hundred and fifty dollars. I thought they had made a mistake. But when I saw they hadn’t, I left it there.)

He had not told anyone at the hospital before he left. He had not called the clinic. He had decided, alone, based on a number at a pharmacy counter, that the medication was not for him, and had been waiting two weeks to find out if that decision had consequences.

Scenario 1: The patient who did not fill the ARNI because of the cost

What the silence before the disclosure means

Sacubitril/valsartan, sold as Entresto, is a guideline-directed first-line agent for heart failure with reduced ejection fraction. In multiple large trials it has reduced heart failure hospitalizations and cardiovascular death compared to enalapril. It is, by most current cardiology guidance, the RAAS-blocking agent of choice for patients with HFrEF who can tolerate it.

It also costs, out of pocket with a high-deductible insurance plan, between $400 and $600 per month at most retail pharmacies. A retired construction laborer on a fixed income does not have $450 for a single medication. He also often does not have a framework for what to do when the pharmacy counter reveals that number, because no one told him that the number was negotiable, that alternatives existed, or that the answer to “cuatrocientos cincuenta dólares” was not “leave it there.”

Tomás had waited two weeks to mention this because he was not sure whether he would be blamed for not finding a solution. He had thought, reasonably, that a medication his doctor prescribed was a medication he should find a way to fill. He had not found a way. He had come to the follow-up expecting to report failure, not to ask for help.

Receiving the disclosure

The nurse did not express surprise. She did not say “oh no, that’s important.” She did not move immediately to solutions before Tomás had finished speaking. She said:

“Tiene razón en decírmelo. Y me alegra que lo haya dicho. Este medicamento tiene un costo que muchos pacientes no pueden pagar de su bolsillo, y hay maneras de resolverlo — pero usted no sabía eso. ¿Puedo explicarle las opciones?”

(You were right to tell me. And I’m glad you said it. This medication has a cost that many patients cannot pay out of pocket, and there are ways to resolve it — but you didn’t know that. Can I explain the options?)

Three things happen in that sentence. First, it confirms that telling her was correct — which is not automatic for a patient who has been rehearsing an apology for two weeks. Second, it names the cost as a structural feature of the medication, not a personal failure to find resources. Third, it opens the conversation toward resolution before Tomás has to ask whether resolution is possible.

The three pathways

The nurse explained three things in plain Spanish.

The first was the manufacturer patient-assistance program. Novartis, the company that makes Entresto, has a program called Entresto Together that provides the medication at no cost or significantly reduced cost for patients who meet income eligibility criteria. Applications can be started at the clinic. The nurse said:

“Lo primero que quiero hacer hoy es ver si usted califica para el programa del fabricante. Se llama Entresto Together. Para muchos pacientes con su nivel de ingresos, el medicamento puede salir gratis o casi gratis. No es un favor — es un programa que ellos tienen exactamente para esto.”

(The first thing I want to do today is see if you qualify for the manufacturer’s program. It’s called Entresto Together. For many patients at your income level, the medication can come out free or almost free. It’s not a favor — it’s a program they have exactly for this.)

The second was the 340B pharmacy option. Federally qualified health centers and certain hospitals have 340B designation that allows them to dispense covered medications at a significantly reduced cost. Tomás’s clinic participated in a 340B program. The nurse explained that they could often fill his prescription through the clinic pharmacy at a fraction of the retail price, and that this was available to him without a separate application.

The third was the bridge option. Sacubitril/valsartan is the guideline-preferred RAAS-blocking agent for HFrEF, but it is not the only option. Enalapril, lisinopril, and other ACE inhibitors cost under ten dollars per month at most pharmacies and remain a supported alternative for patients who cannot access the ARNI. The nurse did not present this as the preferred path, but she named it:

“Si los primeros dos caminos no funcionan, hay un medicamento más antiguo que hace algo parecido — no es lo mismo, pero es una opción mientras encontramos la manera. No vamos a dejarle sin cobertura para su corazón mientras resolvemos esto.”

(If the first two paths don’t work, there is an older medication that does something similar — it’s not the same, but it’s an option while we find the way. We are not going to leave you without coverage for your heart while we figure this out.)

Tomás qualified for the Entresto Together program. The application was submitted that afternoon. He received the medication by mail eleven days later. His cost: zero.

What belongs in the chart

The chart note that matters: patient disclosed sacubitril/valsartan not filled since discharge due to out-of-pocket cost of approximately $450 at retail pharmacy; patient did not know alternatives existed. Entresto Together PAP application initiated today. 340B pharmacy option reviewed. If PAP not approved, bridge ACE inhibitor to be discussed with cardiology. Follow-up call in 5 business days to confirm PAP status. Heart failure regimen at this visit: carvedilol and furosemide taken as directed — no RAAS agent on board since discharge.

The prescriber needs to know that RAAS coverage has been absent for two weeks. That changes the clinical picture. It also changes what the nurse asks at every subsequent follow-up: not “are you taking your medications?” but “was there anything at the pharmacy that was a problem this time?”

Tomás: at his one-month visit, he had been taking the medication for three weeks. His BNP had begun to come down. He had not said anything at the hospital before discharge because he had not known whether the cost was his problem to solve or the clinic’s. He now knew.

Scenario 2: The patient who rations his diuretic to avoid the bathroom at work

Aurelio’s edema, and where it came from

Aurelio Reyes was 58 years old, a bus driver from San José who still worked four days a week running a route through the eastern suburbs. HFrEF, EF 35%, diagnosed eighteen months earlier. He had been on furosemide 40 mg daily since diagnosis.

He arrived at his three-month follow-up with bilateral pitting edema extending to mid-calf, 3+ on both sides. His weight was 6.2 kg above his dry weight from three months earlier. His shoes left marks at mid-sock level. He had said nothing about it.

The nurse assessed the edema and then asked the question she asked at every heart failure follow-up: “¿Cómo le ha ido tomando el furosemide — hay algún día que es más difícil tomarlo?”

(How has it been going with the furosemide — is there any day that it’s harder to take it?)

This is not the question “are you taking your medication?” The second question is binary and invites denial. The first one names difficulty as a possibility and asks which day, which makes the conversation easier to start.

Aurelio said: “Los días que trabajo no lo tomo. Manejo un bus — no puedo pararlo cada hora para ir al baño. Esos días lo dejo para la noche, pero después pienso que ya pa’ qué. Los días que no trabajo, sí lo tomo.”

(The days I work I don’t take it. I drive a bus — I can’t stop it every hour to go to the bathroom. Those days I leave it for the night, but then I think why bother at that point. The days I don’t work, I take it.)

Four working days a week. Three days off. He had been, in effect, taking furosemide approximately three days per week for three months.

Acknowledging the constraint before the mechanism

The nurse did not begin with the clinical explanation. She said:

“Tiene sentido. Si maneja un bus, no puede parar cada hora — eso es real. No es una excusa, es la situación. Lo que me preocupa es que el líquido que el medicamento debería estar quitando se fue acumulando esos días, y por eso estamos viendo esto hoy. Pero lo que quiero entender primero es su horario de trabajo, porque lo que necesitamos es una solución que funcione para usted — no una que le haga imposible trabajar.”

(That makes sense. If you’re driving a bus, you can’t stop every hour — that’s real. It’s not an excuse, it’s the situation. What worries me is that the fluid the medication should have been removing accumulated on those days, and that’s why we are seeing this today. But what I want to understand first is your work schedule, because what we need is a solution that works for you — not one that makes working impossible.)

Aurelio’s schedule: he started his route at 6 AM, finished at 2 PM, Monday through Thursday. He had a thirty-minute break at 10 AM. The route had no off-route stops.

What happens when a daily diuretic becomes three days a week

The nurse drew out the mechanism, because the edema Aurelio had developed was not abstract. He needed to understand it as the direct result of the days without the medication — not as a mysterious progression of his disease.

“El furosemide trabaja todos los días. Su corazón retiene líquido todos los días — no solo los fines de semana. Cuando usted no toma el furosemide un lunes, el martes, el miércoles y el jueves, el líquido que el medicamento debería drenar se queda adentro. El sábado toma el medicamento y drena algo, pero ya son cuatro días acumulados. El cuerpo no puede ponerse al corriente en dos días. Eso es lo que ve en sus tobillos hoy.”

(The furosemide works every day. Your heart retains fluid every day — not only on weekends. When you don’t take the furosemide on Monday, Tuesday, Wednesday and Thursday, the fluid the medication should be draining stays inside. On Saturday you take it and drain some, but it’s already four days of accumulation. The body can’t catch up in two days. That’s what you’re seeing in your ankles today.)

Aurelio: “Pensé que tres días era suficiente. Que el cuerpo lo compensaba.”

(I thought three days was enough. That the body compensated.)

“El corazón con insuficiencia cardíaca no compensa bien — esa es exactamente la problemática. En un corazón sano, el cuerpo tiene mecanismos de reserva. En el suyo, esos mecanismos ya están trabajando al máximo todo el tiempo, y cuando el medicamento no está disponible, no hay margen.”

(A heart with heart failure doesn’t compensate well — that’s exactly the problem. In a healthy heart, the body has backup mechanisms. In yours, those mechanisms are already working at maximum all the time, and when the medication isn’t available, there’s no margin.)

The solution: separating dose from timing

The fundamental problem was not the dose. It was the timing. Aurelio had been told to take furosemide every day. He had been told this without a conversation about when that was possible. The solution was not a new medication, a reduced dose, or a reprimand. It was a conversation about timing that had not happened before.

“Hay una pregunta que le quiero hacer al cardiólogo hoy: ¿puede tomar el furosemide en la noche, después de que llega a casa del trabajo? Si el medicamento se lo toma a las tres de la tarde en lugar de las siete de la mañana, el efecto principal llega cuando usted ya está en casa, no en el bus. Eso es una decisión que tiene que tomar el médico — no yo — porque cambia el timing del efecto y hay consideraciones. Pero es la pregunta correcta.”

(There’s a question I want to ask the cardiologist today: can you take the furosemide in the evening, after you get home from work? If you take the medication at 3 PM instead of 7 AM, the main effect arrives when you’re already home, not on the bus. That’s a decision the doctor needs to make — not me — because it changes the timing of the effect and there are considerations. But it’s the right question.)

The cardiologist agreed to an evening dosing trial on workdays. Furosemide at 7 AM on days off, at 4 PM on work days. The same daily dose. Aurelio understood why.

She also asked Aurelio one more question before he left: “Si en algún momento otro medicamento le crea el mismo problema — que no lo puede tomar por una situación en el trabajo — ¿me llama ese mismo día?”

(If at any point another medication creates the same problem for you — that you can’t take it because of a situation at work — will you call me that same day?)

Aurelio: “Sí. No sabía que eso era posible. Pensé que el horario era parte del medicamento y que no se podía cambiar.”

(Yes. I didn’t know that was possible. I thought the schedule was part of the medication and couldn’t be changed.)

At six weeks: edema resolved to trace, weight back to within 1.2 kg of dry weight. He had taken the furosemide every day of the prior six weeks.

Scenario 3: The patient who stopped his beta-blocker after reading the side-effect list

The pharmacy printout and the decision it produced

Roberto Cisneros was 67 years old, a retired construction foreman from Fresno who had supervised concrete crews for twenty-eight years and who read everything that came into his hands carefully and completely. HFrEF, EF 28%, carvedilol 12.5 mg BID initiated three weeks earlier after his dose had been successfully titrated up from the starting 3.125 mg BID.

He had taken the medication for nine days. Then he had read the pharmacy printout.

The printout listed the following under “serious side effects”: worsening heart failure; shortness of breath; chest pain; rapid or irregular heartbeat; sudden weight gain; swelling of the hands or feet; fainting; death.

Roberto had read this list slowly. He had read it again. He was a patient with heart failure. The list said carvedilol could cause heart failure. He had stopped taking it that evening.

He arrived at his follow-up three weeks after initiation. His resting heart rate was 96. It had been 64 at his last visit when he was still taking the carvedilol. He had not mentioned any of this.

The nurse asked about his medications. Roberto said: “El carvedilol lo dejé de tomar. Leí los efectos secundarios y dice que puede causar insuficiencia cardíaca. Yo ya la tengo. No entendí por qué me lo darían si ya la tengo.”

(I stopped taking the carvedilol. I read the side effects and it says it can cause heart failure. I already have that. I didn’t understand why they would give it to me if I already have it.)

This is a reasonable question. It is the correct question to ask. Nobody had answered it before he made his decision.

Receiving the question before the explanation

The nurse said: “Hizo bien en leerlo. Y su pregunta es buena — es exactamente la pregunta correcta. Hay una explicación, y quiero dársela, porque cuando termine creo que va a entender por qué tiene sentido. ¿Me da unos minutos?”

(You were right to read it. And your question is a good one — it’s exactly the right question. There is an explanation, and I want to give it to you, because when I’m done I think you will understand why it makes sense. Can you give me a few minutes?)

She did not say the list was wrong. She did not say Roberto had made a mistake. She confirmed that reading the printout was the right behavior and that the question it produced was legitimate. This matters, because a patient who is told “oh, you shouldn’t worry about those lists” has received a message to stop reading. That is not the goal. The goal is a patient who reads, asks, and understands.

What the pharmacy printout is, and what it is not

“La lista de efectos secundarios que leyó la escribieron para todas las personas que toman este medicamento — incluyendo personas que lo toman para la presión alta y no tienen insuficiencia cardíaca. Para esas personas, si la dosis es muy alta, puede afectar cómo bombea el corazón. Por eso aparece en la lista. Tiene que aparecer — la FDA exige que aparezca todo lo que es posible que ocurra. Pero lo que posible quiere decir no es probable, y no es lo mismo para usted que para otro paciente.”

(The side-effect list you read was written for everyone who takes this medication — including people who take it for high blood pressure and don’t have heart failure. For those people, at very high doses, it can affect how the heart pumps. That’s why it appears on the list. It has to appear — the FDA requires that everything that can possibly occur is listed. But what “possible” means is not “probable,” and it’s not the same for you as for another patient.)

Roberto: “Entonces no lo escribieron para mí.”

(So they didn’t write it for me.)

“No lo escribieron para usted específicamente. Lo escribieron para cualquier persona que pudiera tomarlo. Usted es un paciente específico con una condición específica, y para usted la razón de tomarlo y la manera de tomarlo son completamente diferentes.”

(They didn’t write it for you specifically. They wrote it for anyone who might take it. You are a specific patient with a specific condition, and for you the reason for taking it and the way of taking it are completely different.)

The mechanism that resolves the paradox

Now the explanation, because Roberto deserved to understand not only that the list was not written for him, but why the medication that can harm a healthy person’s heart is the medication that helps his.

“Cuando el corazón tiene insuficiencia cardíaca — cuando está débil — el cuerpo intenta compensar de una manera que a la larga lo daña. Una de las cosas que hace es hacer que el corazón lata más rápido. Usted tiene el corazón latiendo a noventa y seis por minuto ahora mismo — eso es lo que pasa cuando no tiene el medicamento. Cuando el corazón late así de rápido todo el tiempo, trabaja más y descansa menos entre latidos, y con el tiempo eso lo debilita más.”

(When the heart has heart failure — when it’s weak — the body tries to compensate in a way that eventually damages it more. One of the things it does is make the heart beat faster. You have the heart beating at ninety-six per minute right now — that’s what happens without the medication. When the heart beats that fast all the time, it works more and rests less between beats, and over time that weakens it further.)

“El carvedilol lo que hace es bajar esa velocidad. Lo frena un poco. Eso parece contradictorio — ¿cómo un medicamento que frena el corazón puede ayudar a un corazón que ya está débil? La respuesta es que el corazón débil necesita más tiempo para llenarse entre latidos. Cuando late más despacio, se llena mejor, bombea más eficientemente, y con el tiempo — en semanas o meses — en algunos pacientes la fracción de eyección mejora. No siempre, pero pasa. Es uno de los pocos medicamentos para la insuficiencia cardíaca que puede recuperar función.”

(What carvedilol does is bring that speed down. It slows it a little. That seems contradictory — how can a medication that slows the heart help a heart that is already weak? The answer is that a weak heart needs more time to fill between beats. When it beats more slowly, it fills better, pumps more efficiently, and over time — in weeks or months — in some patients the ejection fraction improves. Not always, but it happens. It is one of the few medications for heart failure that can recover function.)

Roberto was quiet. Then: “¿Y el que está noventa y seis — eso es malo?”

(And the ninety-six — is that bad?)

“Sí. Eso es el corazón trabajando demasiado rápido sin protección. Cuando tenía el medicamento estaba en sesenta y cuatro. Eso es lo que queremos sostener.”

(Yes. That’s the heart working too fast without protection. When you had the medication it was sixty-four. That’s what we want to maintain.)

Roberto: “Entonces no lo leyeron para mí — lo escribieron para otra persona.”

(So they didn’t write it for me — they wrote it for someone else.)

“Exacto. Para otra persona, a otra dosis, por otra razón. Usted es el paciente para quien el medicamento fue diseñado cuando se diseñó para corazones así.”

(Exactly. For another person, at another dose, for another reason. You are the patient this medication was designed for when it was designed for hearts like yours.)

The agreement and what it requires

Roberto agreed to restart the carvedilol. Before he left, the nurse did one more thing. She took the pharmacy printout from the conversation and turned to the back page, where the warnings appeared in the smallest font.

“La próxima vez que lea una lista así, quiero que haga esto: busque el nombre del medicamento arriba, y después lómelo así — ‘este medicamento puede causar X en pacientes sin insuficiencia cardíaca que lo toman por otra razón.’ Si algo le preocupa, llámeme. No porque la lista esté equivocada, sino porque la lista no sabe quién es usted. Yo sí sé.”

(Next time you read a list like this, I want you to do this: find the medication name at the top, and then read it like this — “this medication can cause X in patients without heart failure who take it for another reason.” If something worries you, call me. Not because the list is wrong, but because the list doesn’t know who you are. I do.)

At his four-week follow-up: resting heart rate 68. EF at the six-month echo: 34%, up from 28% at initiation. Roberto had not stopped the medication again. He had called once, to ask about a line on the printout that mentioned bradycardia, and the nurse had explained the target heart-rate range and what to do if it went below 50. He had written the number down.

Three questions worth asking at every heart failure follow-up when medication adherence is uncertain

These three questions produce disclosures that the standard binary adherence question does not reach. “Did you take your medications?” closes the conversation. These open it.

(1) “¿Pudo tomar todos sus medicamentos como le indicaron esta semana — o hubo alguno que fue difícil de conseguir, de pagar, o de tomar por alguna razón?”

(Were you able to take all your medications as directed this week — or was there any one that was difficult to get, to pay for, or to take for any reason?)

(2) “¿Hay alguna situación en que sea difícil tomar un medicamento — horario, trabajo, transporte, costo, algo que leyó, algo que le dijeron?”

(Is there any situation in which it’s hard to take a medication — schedule, work, transportation, cost, something you read, something someone told you?)

(3) “¿Hubo alguno que no quiso tomar después de leer la lista de efectos secundarios, o después de que alguien le dijo algo sobre él?”

(Was there any one you didn’t want to take after reading the side-effect list, or after someone told you something about it?)

The third question is the one most nurses do not ask. It is the one that would have caught Roberto three weeks earlier, before the heart rate climbed to 96, before three weeks of the heart working without the protection that was supposed to be there. A patient who reads a pharmacy printout and has a question deserves a nurse who asks whether that question was ever answered.

→ Also in the heart failure clinic series: outpatient monitoring conversations, advanced failure modes, heart failure action plan, the patient who lives alone, 30-day readmission, transplant conversations.

2026-06-25 · ~25 min read